EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Pseudonatural Products for Chemical Biology and Drug Discovery

Luca C Greiner, Axel Pahl, A Lina Heinzke iD, Barbara Zdrazil iD, Andrew R Leach, Robert J Young, Paul D Leeson iD, Herbert Waldmann iD

Journal of Medicinal Chemistry · 24.07.2025 · 68 (14) · 14137-14170

DOI: 10.1021/acs.jmedchem.5c00643 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 01.07.2025. Verfasst von Luca C Greiner und 7 weiteren Autor:innen. Beteiligte Einrichtung: Max-Planck Institute of Molecular Physiology, Department of Chemical Biology, Otto-Hahn-Strasse 11, Dortmund 44227, Germany. Hauptthemen laut MEDLINE: Drug Discovery, Biological Products. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 142 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Max-Planck-Gesellschaft, Technische Universit?t Dortmund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Natural product (NP) structures have provided invaluable inspiration for the discovery of bioactive compound discovery. In the pseudonatural product (PNP) concept unprecedented combinations of NP fragments combine the biological relevance of NPs with exploration of wider chemical space by fragment-based design. We describe the principles underlying the PNP design and discovery of selected PNPs with unexpected or novel bioactivity. Cheminformatic analyses of ChEMBL 32, the Enamine screening library, phase 1-3 clinical compounds, and approved drugs reveal that ca. 1/3 of historically developed biologically active compounds and of currently commercially available screening compounds are PNPs, and that PNPs are increasing over time. PNPs are 54% more likely to be found in clinical compounds versus nonclinical compounds, and 67% of recent clinical compounds are PNPs. 63% of the core scaffolds in recent clinical compounds are made up of just 176 NP fragments, which suggests that PNPs open up a multitude of unexploited opportunities for drug discovery.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug DiscoveryBiological ProductsHumansDrug Design

Substanzen

Biological Products

Autor:innen und Institutionen

  • Max-Planck Institute of Molecular Physiology, Department of Chemical Biology, Otto-Hahn-Strasse 11, Dortmund 44227, Germany.
  • European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton CB10 1SD, Cambridgeshire, U.K.
  • Blue Burgundy Ltd., Bedfordshire, Ampthill MK45 2AD, U.K.
  • Paul Leeson Consulting Ltd., Nuneaton, Warwickshire CV13 6LZ, U.K.
  • Technical University Dortmund, Faculty of Chemistry and Chemical Biology, Otto-Hahn-Strasse 6, Dortmund 44227, Germany.

ORCID-Profile: A Lina Heinzke, Barbara Zdrazil, Paul D Leeson, Herbert Waldmann

Förderung

  • Max-Planck-Gesellschaft
  • Technische Universit?t Dortmund

Zitieren

APA

Greiner, L. C., Pahl, A., Heinzke, A. L., Zdrazil, B., Leach, A. R., Young, R. J., Leeson, P. D., & Waldmann, H. (2025). Pseudonatural Products for Chemical Biology and Drug Discovery. Journal of Medicinal Chemistry, 68(14), 14137-14170. https://doi.org/10.1021/acs.jmedchem.5c00643

Vancouver

Greiner LC, Pahl A, Heinzke AL, Zdrazil B, Leach AR, Young RJ, et al. Pseudonatural Products for Chemical Biology and Drug Discovery. Journal of Medicinal Chemistry. 2025;68(14):14137-14170. doi:10.1021/acs.jmedchem.5c00643

BibTeX
@article{Greiner2025,
  author = {Greiner, Luca C and Pahl, Axel and Heinzke, A Lina and Zdrazil, Barbara and Leach, Andrew R and Young, Robert J and Leeson, Paul D and Waldmann, Herbert},
  title = {Pseudonatural Products for Chemical Biology and Drug Discovery},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  volume = {68},
  number = {14},
  pages = {14137--14170},
  doi = {10.1021/acs.jmedchem.5c00643}
}
Kostenlos starten →